ADC Therapeutics (ADCT) Long-Term Deferred Tax (2021 - 2022)
ADC Therapeutics' (ADCT) quarterly Long-Term Deferred Tax came in at $37.1 million in Q4 2022, up 42.44% year-on-year from $26.0 million in Q4 2021, and up 42.44% quarter-over-quarter from $26.0 million in Q4 2021.
ADC Therapeutics (ADCT) Long-Term Deferred Tax (2021 - 2022) Analysis & Trends
ADC Therapeutics has disclosed Long-Term Deferred Tax across 2 years of filings, most recently posting $37.1 million for Q4 2022.
- Long-Term Deferred Tax for Q4 2022 came in at $37.1 million, up 42.44% year-over-year; the trailing twelve-month figure through Dec 2022 was $37.1 million (up 42.44% YoY), and the FY2022 annual result was $37.1 million, up 42.44% from the prior year.
- Long-Term Deferred Tax came in at $37.1 million for Q4 2022 at ADC Therapeutics, up from $26.0 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $37.1 million in Q4 2022 to a low of $26.0 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | ADC Therapeutics | 167.24 Mn | -63.76 Mn | 7.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 37.10 Mn |
| Dec 31, 2021 | 26.05 Mn |